SteelPeak Wealth LLC Buys 3,483 Shares of McKesson Corporation $MCK

Key Points

• SteelPeak Wealth increased its McKesson stake by 382.3% in the third quarter, purchasing 3,483 additional shares for a total holding of 4,394 shares valued at approximately $3.76 million. Institutional investors collectively own 85.07% of the company.
• McKesson reported quarterly EPS of $9.93, exceeding the $9.56 consensus estimate, while revenue rose 7.7% year over year to $105.38 billion. The company issued fiscal 2027 EPS guidance of $44.20–$45.00.
• Analysts maintain a “Moderate Buy” consensus rating, with 15 Buy and four Hold ratings and an average price target of $990.35. McKesson also raised its quarterly dividend to $0.94 per share, representing a 0.4% annualized yield.

SteelPeak Wealth LLC raised its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 382.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 4,394 shares of the company's stock after purchasing an additional 3,483 shares during the quarter. SteelPeak Wealth LLC's holdings in McKesson were worth $3,755,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Nvwm LLC lifted its stake in shares of McKesson by 933.3% in the third quarter. Nvwm LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 28 shares during the period. Delos Wealth Advisors LLC acquired a new stake in McKesson during the second quarter worth about $27,000. GK Wealth Management LLC bought a new position in McKesson during the third quarter valued at about $38,000. Clearstead Trust LLC bought a new position in McKesson during the second quarter valued at about $37,000. Finally, Security National Bank of SO Dak bought a new position in McKesson during the second quarter valued at about $39,000. Institutional investors own 85.07% of the company's stock.

McKesson Stock Performance

NYSE:MCK opened at $1,005.39 on Friday. The company has a 50-day moving average of $897.66 and a 200-day moving average of $837.50. The company has a market capitalization of $117.22 billion, a price-to-earnings ratio of 26.90, a PEG ratio of 2.00 and a beta of 0.30. McKesson Corporation has a 52 week low of $723.68 and a 52 week high of $1,014.99.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, beating the consensus estimate of $9.56 by $0.37. The business had revenue of $105.38 billion for the quarter, compared to analyst estimates of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm's revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Sell-side analysts forecast that McKesson Corporation will post 44.71 EPS for the current year.

McKesson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Tuesday, September 1st were paid a dividend of $0.94 per share. This is a positive change from McKesson's previous quarterly dividend of $0.82. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Tuesday, September 1st. McKesson's dividend payout ratio is 10.06%.

Analyst Upgrades and Downgrades

Several research firms have commented on MCK. Wall Street Zen raised McKesson from a "hold" rating to a "buy" rating in a report on Saturday. Wells Fargo & Company lifted their price objective on McKesson from $812.00 to $933.00 and gave the stock an "equal weight" rating in a report on Tuesday, August 11th. UBS Group lifted their price objective on McKesson from $1,080.00 to $1,200.00 and gave the stock a "buy" rating in a report on Friday. Leerink Partners boosted their price objective on McKesson from $1,030.00 to $1,070.00 and gave the company an "outperform" rating in a research report on Wednesday, October 7th. Finally, Evercore restated an "outperform" rating and issued a $950.00 target price (down from $1,000.00) on shares of McKesson in a research note on Thursday, August 6th. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, McKesson currently has an average rating of "Moderate Buy" and a consensus price target of $990.35.

Insider Transactions at McKesson

In other McKesson news, CAO B Jr sold 111 shares of McKesson stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the sale, the chief accounting officer directly owned 521 shares of the company's stock, valued at approximately $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley Lerman sold 301 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is owned by company insiders.

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson's principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.